Deutsche Bank analyst Neena Bitritto-Garg initiated coverage of Neurocrine Biosciences with a Buy rating and $136 price target. The analyst sees potential for share upside into 2024 on crinecerfont in congenital adrenal hyperplasia, which the firm says could be on market as soon as 2025 in the U.S., and from mid/late-stage clinical successes. It thinks the Street is currently underestimating peak sales potential for crinecerfont.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next
- Neurocrine receives FDA Breakthrough Therapy designation for crinecerfont
- Neurocrine price target raised to $139 from $134 at JPMorgan
- Neurocrine announces settlement of INGREZZA ANDA litigation
- Neurocrine price target lowered to $121 from $128 at RBC Capital